Page last updated: 2024-12-08

aurantio-obtusin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

aurantio-obtusin: main anthraquinone in “Jue-Ming-Zi”, therapeutic for hyperlipidemia [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

aurantio-obtusin : A trihydroxyanthraquinone that is 1,3,7-trihydroxy-9,10-anthraquinone which is by methoxy groups at positions 2 and 8, and by a methyl group at position 6. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID155011
CHEMBL ID461288
CHEBI ID37386
SCHEMBL ID3189231
MeSH IDM000602878

Synonyms (25)

Synonym
CHEBI:37386 ,
67979-25-3
1,3,7-trihydroxy-2,8-dimethoxy-6-methylanthracene-9,10-dione
aurantio-obtusin
C17670
aurantioobtusin
CHEMBL461288
FT-0662337
9,10-anthracenedione, 1,3,7-trihydroxy-2,8-dimethoxy-6-methyl-
S9155
1,3,7-trihydroxy-2,8-dimethoxy-6-methyl-9,10-anthracenedione
SCHEMBL3189231
AC-34058
Q-100765
DTXSID90218172
AKOS037514557
1,3,7-trihydroxy-2,8-dimethoxy-6-methylanthraquinone
mfcd13194886
Q27117130
A14740
CS-0008284
HY-N0261
CCG-267807
1,3,7-trihydroxy-2,8-dimethoxy-6-methyl-9,10-dihydroanthracene-9,10-dione
AS-56820

Research Excerpts

Toxicity

ExcerptReferenceRelevance
", mitochondrial dysfunction-mediated apoptosis and LPO-enhanced ferroptosis) over a series of key events (KEs) to the adverse outcome of hepatotoxicity."( An adverse outcome pathway-based approach to assess aurantio-obtusin-induced hepatotoxicity.
Du, J; Hu, M; Huang, Y; Huang, Z; Li, Z; Liang, B; Lin, L; Lin, X; Liu, J; Lu, Z; Meng, H; Wang, B; Xian, H; Yang, X; Ye, R; Zhang, B; Zheng, S; Zhong, Y, 2022
)
0.97

Pharmacokinetics

ExcerptReferenceRelevance
" Pathological state is an important factor affecting the efficacy of drugs, the pharmacokinetic behavior of drugs could be significantly changed when people or animal were under different pathological state."( Nine components pharmacokinetic study of rat plasma after oral administration raw and prepared Semen Cassiae in normal and acute liver injury rats.
Cai, B; Jin, J; Peng, S; Qin, K; Sun, K; Xie, L; Yang, B; Zhen, Y, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
trihydroxyanthraquinoneA member of the class of hydroxyanthraquinones carrying three hydroxy substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1594062Inhibition of baker's yeast alpha-glucosidase using PNPG as substrate preincubated for 15 mins followed by substrate addition and measured after 15 mins
AID1256630Inhibition of sEH (unknown origin) assessed as 6-methoxy-2-naphthaldehyde formation at 50 uM by fluorometry assay using 40 uM cyano-(6-methoxy-naphthalen-2-yl)-methyl ester as substrate2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Constituents of the seeds of Cassia tora with inhibitory activity on soluble expoxide hydrolease.
AID335922Antiplatelet activity in rat platelet rich plasma assessed as drug level causing inhibition of arachidonic acid-stimulated platelet aggregation pretreated 2 mins before arachidonic acid challenge
AID343962Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced EBV-early antigen activation in human Raji cells2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Correlation between reduction potentials and inhibitions of Epstein-Barr virus activation by anthraquinone derivatives.
AID335923Antiplatelet activity in rat platelet rich plasma assessed as drug level causing inhibition of ADP-stimulated platelet aggregation pretreated 2 mins before ADP challenge
AID1594063Antioxidant activity assessed as DPPH radical scavenging activity incubated for 30 mins under dark condition
AID335924Antiplatelet activity in rat platelet rich plasma assessed as drug level causing inhibition of collagen-stimulated platelet aggregation pretreated 2 mins before collagen challenge
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (4.35)29.6817
2010's14 (60.87)24.3611
2020's8 (34.78)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.40 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index6.01 (4.65)
Search Engine Demand Index24.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (95.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]